Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 19 articles:
HTML format
Text format



Single Articles


    September 2018
  1. ANTEL J
    Therapy in Multiple Sclerosis - Coming of Age.
    N Engl J Med. 2018;379:1085-1086.
    PubMed     Text format    


  2. CHITNIS T, Arnold DL, Banwell B, Bruck W, et al
    Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
    N Engl J Med. 2018;379:1017-1027.
    PubMed     Text format     Abstract available


    August 2018
  3. FOX RJ, Coffey CS, Conwit R, Cudkowicz ME, et al
    Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
    N Engl J Med. 2018;379:846-855.
    PubMed     Text format     Abstract available


    January 2018
  4. REICH DS, Lucchinetti CF, Calabresi PA
    Multiple Sclerosis.
    N Engl J Med. 2018;378:169-180.
    PubMed     Text format    


    August 2017
  5. METZ LM, Eliasziw M
    Trial of Minocycline in Clinically Isolated Syndrome of Multiple Sclerosis.
    N Engl J Med. 2017;377:789.
    PubMed     Text format    



  6. Trial of Minocycline in Clinically Isolated Syndrome of Multiple Sclerosis.
    N Engl J Med. 2017;377:788-789.
    PubMed     Text format    


    June 2017
  7. XIA Z, Friedlander RM
    Minocycline in Multiple Sclerosis - Compelling Results but Too Early to Tell.
    N Engl J Med. 2017;376:2191-2193.
    PubMed     Text format    


  8. METZ LM, Li DKB, Traboulsee AL, Duquette P, et al
    Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis.
    N Engl J Med. 2017;376:2122-2133.
    PubMed     Text format     Abstract available


    April 2017
  9. DEISENHAMMER F, Auer M, Hegen H
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1693-4.
    PubMed     Text format    


  10. MILDINER S, Malnick S
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1692-3.
    PubMed     Text format    


  11. SHARP MK
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1692.
    PubMed     Text format    


  12. KORN T, Oukka M
    A BAFFling Association between Malaria Resistance and the Risk of Multiple Sclerosis.
    N Engl J Med. 2017;376:1680-1681.
    PubMed     Text format    


  13. MONTALBAN X, Belachew S, Wolinsky JS
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1694.
    PubMed     Text format    


  14. SCHOERGENHOFER C, Jilma B
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1693.
    PubMed     Text format    


  15. HAUSER SL, Belachew Sh, Kappos L
    Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.
    N Engl J Med. 2017;376:1694.
    PubMed     Text format    


  16. STERI M, Orru V, Idda ML, Pitzalis M, et al
    Overexpression of the Cytokine BAFF and Autoimmunity Risk.
    N Engl J Med. 2017;376:1615-1626.
    PubMed     Text format     Abstract available


    December 2016
  17. MONTALBAN X, Hauser SL, Kappos L, Arnold DL, et al
    Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
    N Engl J Med. 2016 Dec 21. doi: 10.1056/NEJMoa1606468.
    PubMed     Text format     Abstract available


  18. HAUSER SL, Bar-Or A, Comi G, Giovannoni G, et al
    Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    N Engl J Med. 2016 Dec 21. doi: 10.1056/NEJMoa1601277.
    PubMed     Text format     Abstract available


  19. CALABRESI PA
    B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis.
    N Engl J Med. 2016 Dec 21. doi: 10.1056/NEJMe1614717.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: